Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Treatment of Inflammatory Bowel Disease (IBD) Using IL-13 Modulators and Inhibitors

Posted Oct 11 2010 8:00pm

Description of Invention:
Ulcerative colitis (UC), a chronic inflammatory disease of the colorectum, affects approximately 400,000 people in the United States. The cause of UC is not known, although an abnormal immunological response to bacterial antigens in the gut microflora is thought to be involved. Available for licensing are broad claims covering (1) treatments preventing the inflammatory response of colitis by modulating IL-13 and Natural Killer T cell (NKT) activity and (2) methods for screening for therapeutic compounds effective for colitis. NIH scientists and their collaborators have used a mouse model of experimental colitis (oxazolone colitis, OC) to show that IL-13, a Th2 cytokine, is a significant pathologic factor in OC and that neutralizing IL-13 in these animals effectively prevents colitis. Inflammation in this mouse model has also been shown to be effectively blocked by neutralizing IL-13 or by inhibiting the activation of NK-T cells through CD1.

Oxazolone colitis (OC) is a colitis induced by intrarectal administration of a relatively low dose of the haptenating agent oxazolone subsequent to skin sensitization with oxazolone. A highly reproducible and chronic colonic inflammation is obtained that is histologically similar to human ulcerative colitis. Studies show that NKT cells, rather than conventional CD4+T cells, mediate oxazolone colitis, are the source of IL-13, and are activated by CD1 expressing intestinal epithelial cells. Tissue removed from UC patients were also shown to contain increased numbers of nonclassical NKT cells that produce markedly increased amounts of IL-13. In addition, these NKT cells are cytotoxic for epithelial cells, supporting the concept that epithelial damage is a key factor in UC.

Applications:
Development of IL-13 and CD1 based therapeutics to treat or prevent ulcerative colitis.

Development Status:
Small animal model studies.

Inventors:
Warren Strober (NIAID)
Ivan J Fuss (NIAID)
Frank Heller [ex-Schieffele] (NIAID)


Patent Status:
HHS, Reference No. E-131-2002/0
US, , Patent No. 7,666,411, Issued 23 Feb 2010
US, Application No. 12/709,029 filed 19 Feb 2010

Related international patent/patent application filings

Related Technologies:
US, Application No. 11/918,711 filed 14 Apr 2006, Reference No. E-003-2005/0 (IL-13 mutant and chimeric molecules)
US, Application No. 11/920,214 filed 09 Nov 2007, Reference No. E-108-2005/0 (NF-kappa B decoy oligonucleotides)
US, Application No. 60/671,624 filed 15 Apr 2005, Reference No. E-003-2005/0


Relevant Publication:
  1. IJ Fuss et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004 May;113(10):1490-1497. [ PubMed: 15146247 ]
  2. F Heller et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002 Nov;17(5):629-638. [ PubMed: 12433369 ]


Licensing Status:
Available for licensing.


Portfolios:
Internal Medicine
Internal Medicine - Therapeutics
Internal Medicine - Other



For Licensing Information Please Contact:
Suryanarayana Vepa Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vepas@mail.nih.gov
Phone: 301-435-5020
Fax: 301-402-0220


Ref No: 1035

Updated: 10/2010

Post a comment
Write a comment:

Related Searches